The first consensus recommendations on recognition and clinical management of immune-related side effects from cancer immunotherapy are published today in the Journal for ImmunoTherapy of Cancer (JITC).
Researchers at Roswell Park Cancer Institute have initiated a clinical trial based on a unique two-pronged strategy for arming the immune system to more effectively attack cancer cells.
In a new study published in Cell Reports, scientists report an unexpected finding — that the oncogene FOXQ1 suppresses the growth of melanoma cells.
Roswell Park Cancer has joined the Oncology Research Information Exchange Network, a unique research partnership among North America’s top cancer centers. Members of ORIEN contribute to a shared databank and collaborate on clinical research in order to develop new and better treatment options for cancer patients.
A new study from Roswell Park Cancer Institute reports that women with breast cancer who took multivitamin supplements were less likely to develop chemotherapy-induced neuropathy.
New research led by a team from Roswell Park Cancer Institute and published in the journal Nature Methods reports the development of the first tool for detecting changes in GTP levels in living cells.
In new research published in the journal Cancer Research, a team from Roswell Park has shown that "beta blocker" drugs appear to be an effective means of reducing beta-2 receptor signaling and, in the process, may improve the efficacy of checkpoint inhibitor immunotherapy
Roswell Park Cancer Institute has been named a 2017–18 Best Hospital for cancer by U.S. News & World Report. The Buffalo, N.Y., comprehensive cancer center was ranked by the news outlet as 33rd among nearly 900 cancer hospitals reviewed nationwide, and was also recognized as high-performing in urology and lung cancer surgery.
The U.S. Food and Drug Administration has awarded orphan drug status to SurVaxM, a promising immunotherapy vaccine developed at Roswell Park Cancer Institute and being studied as a treatment for glioblastoma, a type of brain cancer.
Roswell Park Cancer Institute and the Mayo Clinic Cancer Center are jointly hosting the 10th annual Spirit of EAGLES: Changing Patterns of Cancer in Native Communities conference, to be held Sept. 21–24 in Niagara Falls, New York.
A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the immune effects of high-dose radiation therapy followed by surgery in patients with advanced kidney cancer may also set the stage for combination treatments with immunotherapy.
Dr. Philip McCarthy of Roswell Park Cancer Institute presents updated findings on CALGB/ECOG 100104 study of lenalidomide maintenance therapy for multiple myeloma, adjusting data to account for crossover effect.
Dr. Kunle Odunsi of Roswell Park Cancer Institute presented an update about an ongoing clinical trial involving T-cell engineering to treat advanced ovarian cancer at the ASCO Annual Meeting in Chicago.
Roswell Park and OmniSeq report that a custom algorithm they developed based on a 54-gene signature accurately predicted response to anti-PD-L1 treatment in 90% of the cases they analyzed.
The authors of a phase II clinical study report that combination therapy with brentuximab vedotin and gemcitabine in patients is “highly active" regimen for patients with Hodgkin lymphoma.
A new study led by researchers at Roswell Park Cancer Institute establishes a connection between a sedentary lifestyle and risk of developing kidney or bladder cancer.
A new meta-analysis by a team from Roswell Park Cancer Institute demonstrates that Enhanced Recovery After Surgery (ERAS) programs are effective in patients requiring many abdominal and pelvic operations, not just those undergoing colorectal surgeries.
Patients who expressed the tumor antigen NY-ESO-1 had more aggressive cancers and were more likely to die early from their disease, according to a large study conducted by Roswell Park Cancer Institute researchers and published online ahead of print in the journal Gynecologic Oncology.
An international team of collaborators retroactively examined the associations between survival among patients diagnosed with invasive epithelial ovarian cancer and those patients’ history of hypertension, heart disease, diabetes, and medications taken for those conditions. They found that while hypertension was linked to better outcomes, diabetes was associated with decreased survival.
Collaborative study with Cleveland Clinic & SUNY Upstate Medical University shows that single high-dose SBRT treatment is as effective as three doses in patients with non-small cell lung cancer
• Team creates calculator to guide treatment choice in esophageal cancer • Tool helps identify which patients may benefit from treatment before surgery • Patients with advanced, aggressive tumors often good pretreatment candidates
• Dairy consumption appears to lower risk for breast cancer • High consumption of yogurt linked to reduced risk of breast cancer • Higher intake of some cheeses tied to slightly increased risk
• New Roswell Park spinoff company will develop next-generation cancer immunotherapies • Novel approach combines unique adoptive T cell therapy with genetically engineered stem cell therapy • Clinical trial planned in ovarian, pancreatic, lung, prostate and other hard-to-treat cancers
BUFFALO, N.Y. — More than 1 in 4 adults and nearly 1 in 10 youth use tobacco, according to findings from the Population Assessment of Tobacco and Health (PATH) Study, published online ahead of print in the New England Journal of Medicine. The PATH Study, established in 2011 through collaboration between the National Institutes of Health’s National Institute on Drug Abuse and the U.S. Food and Drug Administration’s Center for Tobacco Products, is a uniquely large, nationally representative longitudinal study designed to examine tobacco use behaviors and health among the U.S. population over multiple years of follow-up. The PATH Study is being conducted by Westat of Rockville, Md., with Roswell Park Cancer Institute as the scientific lead.
Metastasis, or spread of a tumor from the site of origin to additional organs, causes the vast majority of cancer-related deaths, but our understanding of the molecular mechanisms behind metastasis remains limited. A research team led by Dean Tang, PhD, Chair of the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute, examined the multistep process that leads to metastasis and their work, which illuminates the role of prostate cancer stem cells that promote tumor growth and metastasis, has been published online ahead of print in the journal Nature Communications.
Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of scientists led by Irwin Gelman, PhD, Professor of Oncology in the Department of Cancer Genetics at Roswell Park Cancer Institute, has identified an 11-gene signature unique to advanced recurrent prostate cancer that they believe will help to identify these aggressive and potentially fatal prostate cancers sooner. The findings have been published online ahead of print in the journal Oncotarget.
BUFFALO, N.Y. — Predisposition to cancer and cancer progression can result from gene mutations that cause elevated rates of genetic damage. Similarly, carcinogens, including some that are used in chemotherapy during cancer treatment, act by damaging the DNA. A new study from Roswell Park Cancer Institute offers insights into the mechanisms that can lead to genetic mutations and proposes opportunities for developing prognostic tests for specific blood disorders and blood cancers based on these striking findings. The study has been published online ahead of print in the journal PLOS Genetics.
One of the main reasons cancer remains difficult to treat is that cancer cells have developed a multitude of mechanisms that allow them to evade destruction by the immune system. One of these escape mechanisms involves a type of immune cell called myeloid-derived suppressor cells (MDSCs). A recent study led by Sharon Evans, PhD, Professor of Oncology and Immunology at Roswell Park Cancer Institute, provides new insight into how MDSCs enable tumor cells to circumvent immune attack and offer the potential for improving cancer immunotherapy. The research has been published today in the journal eLife.
A new clinical study underway at Roswell Park Cancer Institute is the first to test the combination of the immunotherapy pembrolizumab with two other drugs as treatment for recurrent epithelial ovarian cancer, and is also the first ovarian cancer clinical trial to incorporate analysis of patients’ microbiomes
Spurred by NYS Trade Mission to Cuba in 2015, Buffalo cancer center will conduct a clinical trial with CIMAvax-EGF, groundbreaking immunotherapy for lung cancer developed in Cuba — becoming the first American center to receive FDA authorization to sponsor a clinical trial offering a Cuban-made therapy to U.S. patients — and will work to speed this and other innovative therapies to patients worldwide through a historic new business venture with Cuban research institute
Currently, human papillomavirus (HPV) vaccination rates remain low across the U.S., with fewer than 40% of girls and just over 21% of boys receiving the recommended vaccine series. Research from Roswell Park Cancer Institute has identified barriers that need to be overcome to improve vaccination rates, as well as possible strategies for doing so. The study has been published online ahead of print in the Journal of Cancer Education.
African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men — even when they have more aggressive disease, according to new research from Roswell Park Cancer Institute and Vanderbilt University Medical Center. The study, senior authored by Willie Underwood, III, MD, MPH, MSci, of Roswell Park, has been published online ahead of print in the journal Urology.
BUFFALO, N.Y. — What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a study based on 10 years of prospectively collected data on robot-assisted cystectomies, or surgeries to remove the bladder. The researchers, who shared their findings in a recent issue of the journal Urology, report that centers that carefully track various aspects of care can better predict patient outcomes and improve patient care.
A new study led by Anurag Singh, MD, of Roswell Park Cancer Institute and presented at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting suggests that a single high-intensity SBRT dose can be as effective as three slightly lower doses of radiation.
BUFFALO, N.Y. — Roswell Park Cancer Institute scientists report that several flavorings added to electronic cigarettes impact the toxicity of the devices and that, among the tested flavors, strawberry was the most toxic. The researchers also confirmed an earlier finding that increasing the battery output voltage of these devices significantly increases toxicity. The study has been published online ahead of print in the journal Tobacco Control.
New insights on age-related diseases may hold the key to both delaying aging and, in the process, reducing the occurrence of diseases including cancer. These findings have been reported by a team from Roswell Park Cancer Institute and Everon Biosciences in the journal Aging.
New research from Roswell Park Cancer Institute offers clinicians treating patients with advanced liver cancer a way of determining which patients may benefit most from the targeted therapy sorafenib.
While active surveillance is often recommended for patients with nonaggressive prostate cancer to reduce unnecessary treatment, the challenge for clinicians is to monitor and distinguish early-stage tumors from advanced cancers. A team of scientists led by researchers from Roswell Park Cancer Institute have demonstrated that photoacoustic imaging (PAI) may be an effective tool for more accurately viewing and monitoring prostate cancer. The new research has been published in the June 2016 issue of the Journal of Biomedical Optics.
Researchers used deep T-cell receptor (TCR) sequencing to evaluate the clonal composition of tumor-infiltrating lymphocytes, or TILs, and identify novel prognostic biomarkers in ovarian cancer.
Roswell Park researchers evaluated the overall and site-specific incidence of cancer among patients registered in USIDNET, and found increased cancer incidence rates, especially in lymphomas, among patients with primary immunodeficiency diseases.
A study led by researchers at Roswell Park Cancer Institute and Columbia University Medical Center used advanced imaging methods to evaluate obesity, and suggests a relationship between obesity and disease relapse.
In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed.
Lenalidomide maintenance following stem cell transplant now a standard of care for people with multiple myeloma
An early-stage clinical trial at Roswell Park will assess whether the SurVaxM cancer vaccine is a safe and effective treatment option for patients with multiple myeloma, in combination with lenalidomide
Researchers in the Center for Immunotherapy at Roswell Park Cancer Institute (RPCI) have evaluated the human leukocyte antigen (HLA), a group of genes that help regulate the body’s immune system, for underlying differences in ovarian cancer patients’ response to therapy. The scientists report that women with certain types of HLA may have an increased risk of ovarian cancer and may also respond better to immunotherapy. The research was recently published online ahead of print in the journal Gynecologic Oncology.
Only 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit. The research was published online ahead of print in JAMA Oncology, a journal of the American Medical Association.
Even 30 minutes of exercise per week has the potential to significantly reduce a woman’s risk of developing cervical cancer, according to a study from scientists at Roswell Park Cancer Institute (RPCI). The case-control study was recently published in the Journal of Lower Genital Tract Disease.
Improper functioning of the mitochondria may help account for the fact that african-american men with prostate cancer respond poorly to conventional chemotherapy
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right